StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc (VRTX) stock

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$536.45+2.25 (+0.42%)

Close on Nov 18, 2026Market cap $135.97BP/E 31.2Yield –

Vertex Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vertex Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $3.80B, up 8.5% year over year. For fiscal 2025 it was $3.19B. The highest annual figure on record is $3.93B in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.19B–
FY2024Dec 31, 2024-$790.30M-123.7%
FY2023Dec 31, 2023$3.34B-15.0%
FY2022Dec 31, 2022$3.93B+63.0%
FY2021Dec 31, 2021$2.41B-19.5%
FY2020Dec 31, 2020$2.99B+100.4%
FY2019Dec 31, 2019$1.49B+27.2%
FY2018Dec 31, 2018$1.17B+57.6%
FY2017Dec 31, 2017$745.52M+315.2%
FY2016Dec 31, 2016$179.54M–
FY2015Dec 31, 2015-$410.73M–
FY2014Dec 31, 2014-$624.31M–
FY2013Dec 31, 2013-$112.06M-157.0%
FY2012Dec 31, 2012$196.70M+80.2%
FY2011Dec 31, 2011$109.14M–
FY2010Dec 31, 2010-$673.50M–
FY2009Dec 31, 2009-$451.08M–
FY2008Dec 31, 2008-$258.66M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.01B+9.3%
Q1 FY2026Mar 31, 2026$1.29B+66.4%
Q4 FY2025Dec 31, 2025$348.60M-29.1%
Q3 FY2025Sep 30, 2025$1.14B-12.5%
Q2 FY2025Jun 30, 2025$927.40M–
Q1 FY2025Mar 31, 2025$778.20M-37.2%
Q4 FY2024Dec 31, 2024$492.00M+178.8%
Q3 FY2024Sep 30, 2024$1.30B+6.1%
Q2 FY2024Jun 30, 2024-$3.82B-455.7%
Q1 FY2024Mar 31, 2024$1.24B+44.3%
Q4 FY2023Dec 31, 2023$176.50M-83.1%
Q3 FY2023Sep 30, 2023$1.23B+36.2%
Q2 FY2023Jun 30, 2023$1.07B-1.1%
Q1 FY2023Mar 31, 2023$857.80M-3.9%
Q4 FY2022Dec 31, 2022$1.04B+12.0%
Q3 FY2022Sep 30, 2022$901.30M+3.0%
Q2 FY2022Jun 30, 2022$1.09B–
Q1 FY2022Mar 31, 2022$892.60M+5.0%
Q4 FY2021Dec 31, 2021$933.20M+110.3%
Q3 FY2021Sep 30, 2021$874.80M+19.4%
Q2 FY2021Jun 30, 2021-$249.60M-124.5%
Q1 FY2021Mar 31, 2021$850.10M+6.8%
Q4 FY2020Dec 31, 2020$443.84M+3.4%
Q3 FY2020Sep 30, 2020$732.95M+136.1%
Q2 FY2020Jun 30, 2020$1.02B+128.1%
Q1 FY2020Mar 31, 2020$796.25M+159.6%
Q4 FY2019Dec 31, 2019$429.27M+43.6%
Q3 FY2019Sep 30, 2019$310.50M-13.9%
Q2 FY2019Jun 30, 2019$447.39M+53.2%
Q1 FY2019Mar 31, 2019$306.74M+37.3%
Q4 FY2018Dec 31, 2018$298.93M+62.0%
Q3 FY2018Sep 30, 2018$360.44M+153.6%
Q2 FY2018Jun 30, 2018$292.09M+77.8%
Q1 FY2018Mar 31, 2018$223.38M-12.3%
Q4 FY2017Dec 31, 2017$184.53M+42.0%
Q3 FY2017Sep 30, 2017$142.13M+174.5%
Q2 FY2017Jun 30, 2017$164.28M–
Q1 FY2017Mar 31, 2017$254.59M–
Q4 FY2016Dec 31, 2016$129.94M–
Q3 FY2016Sep 30, 2016$51.77M–

More Vertex Pharmaceuticals figures

See a number that looks wrong?